Platelet Rich Plasma (PRP)

Currently we offer two different types of PRP systems. One produces a high concentration of Leucocyte Rich PRP in 15 minutes or a Leucocyte poor PRP in 20 minutes. Our second system has the unique ability of not only producing highly concentrated Leucocyte Rich or Leucocyte Poor PRP, but also has the unique ability to concentrate the Platelet Poor Plasma in the same kit. 

Our PRP system processes autologous whole blood effectively and efficiently at the point-of-care. The system recovers the greatest percentage of platelets by allowing selection of the platelet concentrate from user-defined portions of the centrifuged stack. Our PRP system allows for a broad range of hematocrits which expands the ability to customize the contents of the platelet concentrate.

Our PRR system is designed to be filled with 45-60ml of whole blood and one can expect to yield 3-5ml of highly concentrated PRP from the buffy coat region of the centrifuged stack and if more volume is desired then one can obtain additional volume by adding back platelet poor plasma. This device can provide both PRP and PPP from a single operation, which can be used per the physician’s discretion.

Our advanced PRP system has the unique ability to concentrate proteins from platelet poor plasma (PPP) by transferring the PPP through hundreds of hollow, nanoporous fibers. During this process, water and salt ions are pushed out while the beneficial proteins are retained and concentrated. This process can be performed in such a way that allows the delivery of desired volume to the physician.

The PPP contains proteins like Alpha-2 Macroglobulin (A2M), Interleukin-1 Receptor Antagonist Protein (IRAP), Vascular Endothelial Growth Factor (VEGF), Platelet-derived Growth Factor (PDGF), Transforming Growth Factor Beta (TGF-Beta), Fibroblast Growth Factor (FGF), Fibronectin and Fibrinogen. 

A2M is a powerful natural plasma protease inhibitor, cytokine carrier, and ligand for cell-signaling receptors, and is synthesized primarily in the liver but dispersed through the blood plasma in whole blood and bone marrow. A2M stops the progression of Osteoarthritis (OA) by preventing degenerative cartilage breakdown and assisting with cartilage repair. It can also inhibit inflammatory cytokines, and it thus disrupts inflammatory cascades. In its plasma-soluble tetramer form, it encapsulates matrix metalloproteinases (MMPs) and other destructive enzymes common to arthritic tissue and slows or halts the breakdown of articular cartilage surfaces and other forms of extracellular matrix (ECM). A2M also binds pro-inflammatory molecules TNF-α, TGF-β, and IL-1. While IRAP is present at much higher levels in bone marrow aspirate, the amount available in the whole blood is still concentrated with the Plus system.